Overview

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Status:
Terminated

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.

Phase:

Phase 2

Details

Lead Sponsor:

Biogen

Treatments:

Antibodies, Monoclonal
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine